Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 0.59 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.59 |
| ▸ | HSD11B2 | P80365 | 10/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14277201 | 0.86 | HSD11B1 (0.66) | HSD11B1HSD17B1HSD11B2POLB | |
| SCHEMBL14277197 | 0.86 | HSD11B1 (0.66) | HSD11B1HSD17B1HSD11B2POLB | |
| SCHEMBL14277194 | 0.86 | HSD11B1 (0.66) | HSD11B1HSD17B1HSD11B2POLB | |
| SCHEMBL14277193 | 0.84 | HSD11B1 (0.63) | HSD11B1HSD17B1HSD11B2POLB | |
| SCHEMBL14382298 | 0.82 | HSD11B1 (0.72) | HSD11B1HSD17B1HSD11B2POLB | |
| SCHEMBL5253884 | 0.79 | HSD11B1 (0.57) | HSD11B1HSD17B1HSD11B2POLB | |
| Trifluoroacetic Acid SCHEMBL5098023 | 0.76 | HSD11B1 (0.53) | HSD11B1HSD17B1HSD11B2 | |
| Trifluoroacetic Acid SCHEMBL5095893 | 0.76 | HSD11B1 (0.53) | HSD11B1HSD17B1HSD11B2 | |
| Trifluoroacetic Acid SCHEMBL5104740 | 0.76 | HSD11B1 (0.53) | HSD11B1HSD17B1HSD11B2 | |
| SCHEMBL5095978 | 0.74 | HSD11B1 (1.00) | HSD11B1HSD17B1HSD11B2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474139-B1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO INC (US) | 2007-11-21 | — | — | EP | claimed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329683-B2 | 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1474139-B1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO INC (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070720-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD17B1 2/4885HSD11B2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.